NEA Management Company LLC's Q1 2026 13F: 1 new position, 2 exits
Form 13F-HR for the quarter ended Mar 31, 2026 · filed May 15, 2026 · 26 reported positions · accession 0001072613-26-000458
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Exited | Rhythm Pharmaceuticals, Inc. (RYTM) | 15.9% | — | −15.9 pts | −2.91M sh | −100% |
| New | Spyglass Pharma, Inc. (SGP) | — | 10.9% | +10.9 pts | +7.39M sh | new |
| Reduced | Celcuity Inc. (CELC) | 18.0% | 14.8% | −3.2 pts | −1.25M sh | −35% |
| Increased | Zenas BioPharma, Inc. (ZBIO) | 6.5% | 4.5% | −2.1 pts | +500K sh | +14% |
| Reduced | Gossamer Bio, Inc. (GOSS) | 2.9% | 0.0% | −2.8 pts | −17.09M sh | −94% |
| Exited | Synlogic, Inc. (SYBX) | 0.2% | — | −0.2 pts | −2.92M sh | −100% |
| Increased | Korro Bio, Inc. (KRRO) | 0.4% | 0.8% | +0.4 pts | +207K sh | +19% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 87.6% of the equity book
Changes in the top 10 this quarter: SGP entered · RYTM left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Arcellx, Inc. (ACLX) | 10.1% | 19.9% | |
| 2 | Celcuity Inc. (CELC) | 18.0% | 14.8% | |
| 3 | Spyglass Pharma, Inc. (SGP) | 0.0% | 10.9% | Entered the top 10 |
| 4 | Trevi Therapeutics, Inc. (TRVI) | 8.4% | 9.0% | |
| 5 | Savara, Inc. (SVRA) | 7.5% | 7.6% | |
| 6 | Monte Rosa Therapeutics, Inc. (GLUE) | 6.2% | 7.2% | |
| 7 | MBX Biosciences, Inc. (MBX) | 5.8% | 6.1% | |
| 8 | Zenas BioPharma, Inc. (ZBIO) | 6.5% | 4.5% | |
| 9 | Coursera, Inc. (COUR) | 4.8% | 4.3% | |
| 10 | Aurinia Pharmaceuticals, Inc. (AUPH) | 3.2% | 3.3% | |
| — | Rhythm Pharmaceuticals, Inc. (RYTM) | 15.9% | 0.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).